| Osteoporosis, the loss of bone mass and | | | | protecting effect on bone, and reduced levels of |
| structure, is made haste by the unexpected drop | | | | the hormone trigger bone loss. Due to |
| in estrogen levels that happens as a woman | | | | chemotherapy or surgery, lots of its survivors |
| enters menopause, either in nature, by surgical | | | | feel a loss of ovarian function, and as a result, a |
| taking away of the ovaries before age 45, or by | | | | drop in estrogen levels. Women who were |
| premature menopause caused by breast cancer | | | | premenopausal before their cancer treatment |
| treatment. Estrogen keeps the bones; hence | | | | tend to experience menopause earlier than those |
| estrogen shortage is an exact risk factor for | | | | who have not had the disease. |
| osteoporosis. | | | | Powerful chemotherapy drugs and |
| Osteoporosis could happen at roughly age | | | | estrogen-blocking hormone treatments are very |
| forty-five years or anytime after. It is particularly | | | | effectual in treating breast cancer. But in the |
| significant for women experience undertaking | | | | progression they might be putting women at risk |
| treatment for breast cancer to be informed | | | | of another disease: osteoporosis. |
| concerning the risk factors, detection and | | | | For premenopausal women treated for breast |
| prevention of osteoporosis. | | | | cancer, osteoporosis is a matter as well. As well |
| While the precise cause of breast cancer is not | | | | as the likely effect of chemotherapy on bones, |
| identified, the risk of developing it enhances with | | | | the cancer treatment might stimulate early |
| age. The risk is chiefly high in women over the | | | | menopause, putting this group at a similar risk as |
| age of 60. Due to their age, these women are | | | | older women in menopause. |
| already at increased risk for osteoporosis. Given | | | | Certain drugs applied to treat breast cancer might |
| the increasing occurrence of the disease and the | | | | assist prevent osteoporosis. The drug tamoxifen |
| development of long-term survival rates, bone | | | | is utilized to prevent estrogen from fueling cancer |
| health and fracture prevention have become | | | | cell development. But since it is not stopping the |
| significant health issues amongst its survivors. | | | | body's creation of estrogen such as aromatase |
| Both osteoporosis and invasive breast cancer | | | | inhibitors, tamoxifen has been exposed to add to |
| frequently have no symptoms as long as the | | | | bone density in postmenopausal women. |
| early stages of the disease. Postmenopausal | | | | Tamoxifen is utilized by women who have been |
| women ought to be conscious of their individual | | | | diagnosed with the cancer as well as women at |
| risks for each of these diseases. | | | | high risk for the disease. Additionally, the drug |
| Women who have had breast cancer treatment | | | | raloxifene, which is applied to treat osteoporosis, |
| perhaps at increased risk for osteoporosis and | | | | was lately discovered to be effectual in |
| break for some reasons. First, estrogen has a | | | | preventing the cancer in women at high risk. |